CVS Analyst Day This Friday, 10/8

JP Morgan has published a research report for CVS Caremark Corporation

in anticipation of the company's Analyst Day this Friday, October 8. In the report, JP Morgan writes "We don't believe the Walgreen Company

dispute materially impacted the selling season, and that the company could report $1 billion in 2011 net new business. We look for incremental commentary on the Aetna

agreement, which we believe served as a key validator of the integrated model. In addition, we expect the company to focus on its strong clinical offering, as well as Maintenance Choice and Pharmacy Advisor. We also look for incremental detail on plans to streamline the PBM operations. Taking this into account, we believe the PBM segment should return to high single/low double digit operating profit growth in 2011." JP Morgan maintains its Overweight rating but has raised the price target from $39 to $44. CVS Caremark closed yesterday at $31.43.